Renal Sarcoidosis with Hypercalciuria or Mild Hypercalcemia — What to Do When Hydroxychloroquine Has Not Normalized Calcium
Clinical Scenario
This protocol addresses patients with renal sarcoidosis presenting with hypercalciuria or mild hypercalcemia (serum calcium 11 mg/dl or less) and no nephrolithiasis, in whom a prior trial of hydroxychloroquine did not achieve normalization of serum and urine calcium levels.
About This Condition
In isolated hypercalciuria, initial management may include reduction in calcium intake, increased fluid intake, and avoidance of sun exposure. Mild hypercalcemia may similarly be addressed with dietary calcium reduction and increased fluids. When these measures and a first-line agent have not been sufficient, escalation to the next treatment step is appropriate.
Previous Line — Target Not Reached
Hydroxychloroquine was used as the first-line agent with the goal of normalizing serum and urine calcium levels. This protocol applies when that target has not been achieved and escalation is required.
Next-Line Approach (Overview Only)
Escalation involves a corticosteroid-class agent. The specific agent selection, complete regimen, and clinical decision algorithm are available in the full structured protocol.
Treatment goal: Normalization of serum and urine calcium levels.
References
- In isolated hypercalciuria, treatment may begin with a reduction in calcium intake, increased fluids and avoidance of sun.
- Mild hypercalcemia may also be treated with a reduction in dietary calcium and increased fluid intake.
- For more significant hypercalcemia (e.g. Ca >11 mg/dl) or nephrolithiasis, corticosteroid therapy is usually implemented at 20-40 mg daily.
View source ↗